Panacea Biotec has secured substantial additional vaccine orders from UNICEF, strengthening its position as a key supplier of WHO pre-qualified vaccines. The pharmaceutical company received updates to its existing UNICEF contract for supplying the pentavalent vaccine Easyfive-TT (DTwP-HepB-Hib) for the 2023-2027 period, as well as new awards for pentavalent and polio vaccines.

Contract Value Increases and New Awards

The UNICEF contract updates demonstrate significant growth in order volumes across multiple years:

The combined additional orders total approximately $8.93 million, representing around ₹80.00 crores in new business for the company.

Polio Vaccine Supply Agreement

Beyond the pentavalent vaccine contract updates, Panacea Biotec also secured a significant polio vaccine order from UNICEF in October. The company received a letter of award as part of a long-term agreement to supply bivalent oral polio vaccine (bOPV) in both 10 and 20-vial presentations.

Market Performance

The positive developments were reflected in the company's stock performance, with shares closing at ₹359.50 on December 24, registering a gain of 0.93% on the day. This uptick suggests investor confidence in the company's expanding vaccine supply partnerships with international organizations.

Strategic Significance

These UNICEF contracts underscore Panacea Biotec's capabilities in manufacturing WHO pre-qualified vaccines and its role in global immunization programs. The pentavalent vaccine Easyfive-TT combines protection against diphtheria, tetanus, whooping cough, hepatitis B, and Haemophilus influenzae type b, making it a crucial component of childhood immunization schedules worldwide.

The additional orders, including contract value increases for 2026-2027 and new awards for pentavalent and polio vaccines, further solidify Panacea Biotec's position as a key player in the global vaccine market and its commitment to supporting UNICEF's immunization efforts.

Panacea Biotec Limited , a prominent player in the pharmaceutical industry, has announced significant changes in its key management personnel following the resignation of CFO Devender Gupta. The company's Board of Directors has approved new appointments to ensure continuity in financial and corporate governance functions.

Key Management Appointments

The Board of Directors, in its meeting held on December 15, 2025, approved the following key appointments pursuant to Regulation 30 of SEBI LODR Regulations:

New CFO Profile and Background

Vinod Goel, aged about 60 years, brings extensive experience to his new role. He is a fellow member of the Institute of Company Secretaries of India and an associate member of the Institute of Cost Accountants of India. Goel holds B.Com.(Hons.), M.Com. and LL.B. degrees and has over 35 years of post-qualification experience in corporate governance, contracts negotiation, litigation management, costing, finance, internal audit, funds raising, investor relations, mergers & acquisitions, and corporate restructuring.

Goel has been associated with Panacea Biotec Limited since 1999 and has held various senior-level positions. He was previously serving as Group CFO and Head Legal Company Secretary of the company. Consequently, he will cease to be the Company Secretary and Compliance Officer with effect from December 15, 2025.

New Company Secretary Appointment

Ankit Jain, aged about 38 years, has been appointed as the new Company Secretary and Compliance Officer. He is an associate member of the Institute of Company Secretaries of India (A29499) and holds B.Com. and LL.B. degrees along with a Diploma in taxation laws and IPR. Jain brings around 15 years of experience in corporate governance, regulatory compliance, litigation management, contract management, merger & acquisition, and strategic planning.

Jain was previously working as Assistant General Manager-Legal of the company's wholly-owned subsidiary, Panacea Biotec Pharma Limited, since March 2024, where he was actively engaged in secretarial and legal functions.

Transition Context

These appointments follow the resignation of Devender Gupta from the position of Chief Financial Officer, who stepped down on December 15, 2025, citing personal reasons. The appointments were made based on the recommendation and approval of the Nomination Remuneration Committee and Audit Committee.

Revised Key Managerial Personnel Structure

The company has revised its policy for determining materiality of events and authorized the following Key Managerial Personnel for disclosure purposes under SEBI LODR Regulations, effective December 16, 2025:

The Board meeting commenced at 3:00 PM and concluded at 3:36 PM on December 15, 2025. These strategic appointments demonstrate the company's commitment to maintaining strong financial leadership and corporate governance standards during this management transition.